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HL2 is a LIM-domain protein expressed in myoblasts
but down-regulated in malignant rhabdomyosarcoma
cells, suggesting an important role of FHL2 in muscle
development. To investigate the importance of FHL2 during
myoblast differentiation, we performed a yeast two-hybrid
screen using a cDNA library derived from myoblasts induced
for differentiation. We identiﬁed 
 
 
 
-catenin as a novel inter-
action partner of FHL2 and conﬁrmed the speciﬁcity of
association by direct in vitro binding tests and coimmuno-
precipitation assays from cell lysates. Deletion analysis of
 
both proteins revealed that the NH
 
2
 
-terminal part of 
 
 
 
-catenin
is sufﬁcient for binding in yeast, but addition of the ﬁrst
armadillo repeat is necessary for binding FHL2 in mammalian
F
 
cells, whereas the presence of all four LIM domains of
FHL2 is needed for the interaction. Expression of FHL2
counteracts 
 
 
 
-catenin–mediated activation of a TCF/LEF-
dependent reporter gene in a dose-dependent and muscle
 
cell–speciﬁc manner. After injection into 
 
Xenopus
 
 embryos,
FHL2 inhibited the 
 
 
 
-catenin–induced axis duplication.
C2C12 mouse myoblasts stably expressing FHL2 show
increased myogenic differentiation reﬂected by accelerated
myotube formation and expression of muscle-speciﬁc
proteins. These data imply that FHL2 is a muscle-speciﬁc
repressor of LEF/TCF target genes and promotes myogenic
differentiation by interacting with 
 
 
 
-catenin.
 
Introduction
 
LIM domains, characterized by a double zinc finger motif,
define the expanding family of LIM proteins involved in
protein–protein interactions and transcriptional regulation
(Beckerle, 1997; Dawid et al., 1998). LIM-only proteins are
composed exclusively of LIM domains, whereas LIM-plus
 
proteins combine LIM domains with other functionally
active sites (Dawid et al., 1998). Among the LIM-only pro-
teins, a subfamily containing four and a half LIM domains
has been described. Of the five members, FHL1, FHL2, and
FHL3 are mainly expressed in skeletal and heart muscles
(Chu et al., 2000b), whereas FHL4 and ACT are highly ex-
pressed in testis (Fimia et al., 1999; Morgan and Madgwick,
1999). Recent studies suggest that FHL proteins may act as
 
co-regulators involved in the modulation of tissue-specific gene
expression by interacting with different transcription factors.
 
FHL1 interacts with the mammalian orthologue of the 
 
Dro-
sophila
 
 transcription factor suppressor of hairless (Taniguchi et
al., 1998); FHL2 acts as a coactivator of the androgen receptor
(Muller et al., 2000); FHL3 and to a lesser extent FHL2,
enhance CREB-mediated activation of transcription (Fimia et
al., 2000); and ACT functions as a coactivator of c-AMP
response element modulator (CREM; Fimia et al., 1999).
FHL2, the first LIM-only protein described with four and
a half LIM domains (Genini et al., 1997), was primarily
identified as down-regulated in rhabdomyosarcomas LIM-
domain protein (DRAL).* Although FHL2/DRAL induces
apoptosis in a human rhabdomyosarcoma cell line (Scholl et
al., 2000), the function of the protein in normal myoblasts
and cardiomyocytes, where it is predominantly expressed
(Genini et al., 1997; Chu et al., 2000b), remained unclear
because FHL2-deficient mice maintain normal cardiac func-
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tion (Chu et al., 2000a). Only the hypertrophic response to
 
 
 
-adrenergic stimulation was reported to be slightly modi-
fied in FHL2 knock-out mice (Kong et al., 2001). FHL2
seems to have a dual function. Although it interacts with the
cytoplasmic domain of several integrin chains (Wixler et al.,
2000), it also acts as a transcriptional coactivator of the an-
drogen receptor (Muller et al., 2000). This duality is also re-
flected by the subcellular localization of FHL2 in the nu-
cleus as well as in the cytoplasm and at focal contacts (Scholl
et al., 2000; Wixler et al., 2000). These findings indicate
that FHL2 may mediate signals from the membrane to the
nucleus, though no interaction of FHL2 with transcription
factors in muscle precursor cells has been reported.
A similar dual function has been shown for 
 
 
 
-catenin, a
member of the armadillo-repeat protein family that binds to
the cytoplasmic domain of cadherins (Kemler, 1993; Hinck
et al., 1994) or interacts with TCF transcription factors in
the nucleus. The subcellular localization of 
 
 
 
-catenin de-
pends on its stability in the cytoplasm. In the absence of
Wnt signaling, glycogen synthase kinase 3
 
 
 
 phosphorylates
 
 
 
-catenin, which is subsequently ubiquitinated by 
 
 
 
TrCP
and degraded via proteasomes (Aberle et al., 1997). On Wnt
activation, cytosolic 
 
 
 
-catenin is stabilized and translocates
to the nucleus, where it associates with HMG box–contain-
ing transcription factors of the TCF/LEF family (Behrens et
al., 1996; Molenaar et al., 1996; Hsu et al., 1998; Galceran
et al., 1999). Although some TCFs can repress transcription
by interaction with corepressors in the absence of 
 
 
 
-catenin,
association with 
 
 
 
-catenin causes activation of TCF/LEF
target genes (Miller and Moon, 1997; Nusse, 1997; Hecht
and Kemler, 2000; Seidensticker and Behrens, 2000).
Vertebrate skeletal muscle cells arise from mesodermal
stem cells, which subsequently differentiate into determined
myogenic myoblasts. During myogenesis, myoblasts exit the
cell cycle, fuse into multinucleated myotubes, and express
muscle-specific proteins (Nadal-Ginard, 1978; Brand-Saberi
and Christ, 1999). This complex multi-step process can be
driven by a variety of myogenic inducers such as growth fac-
tors, including Wnts (Munsterberg et al., 1995), cell adhe-
sion molecules, and transcription factors such as myogenic
regulatory factors MyoD, Myf5, and myogenin (Zeschnigk
et al., 1995; Molkentin and Olson, 1996; Yun and Wold,
1996). It has been reported that Wnt1 may regulate Myf5
expression, whereas Wnt7a induces MyoD during embryo-
genesis, thus stressing the importance of Wnt signaling for
muscle development (Cossu and Borello, 1999).
Here, we report that FHL2 interacts with 
 
 
 
-catenin in
mouse myoblasts and down-regulates 
 
 
 
-catenin–mediated
activation of a TCF/LEF-dependent reporter gene in these
cells. Furthermore, myoblasts overexpressing FHL2 show an
increased myogenic differentiation potential. These data im-
ply that FHL2 promotes myogenic differentiation by re-
pressing 
 
 
 
-catenin target genes involved in proliferation.
 
Results
 
Identification of 
 
 
 
-catenin as a novel interaction 
partner of FHL2
 
A yeast two-hybrid screen of a cDNA library derived from
mouse myoblasts induced to differentiate into myotubes was
 
performed with FHL2 as bait. Of 40 isolated clones, four
harbored inserts corresponding to cDNA-encoding mouse
 
 
 
-catenin. These inserts contained most of the 
 
 
 
-catenin
coding region, with the shortest clone lacking the first 24
amino acids. None of the 
 
 
 
-catenin clones showed an inter-
action with the GAL4 DNA binding domain alone or with a
control bait protein (unpublished data). Consistent with the
yeast two-hybrid data, bacterially expressed GST–FHL2 ef-
ficiently interacted with in vitro-translated 
 
35
 
S-radiolabeled
 
 
 
-catenin (Fig. 1 A). Moreover, using FHL2-specific pAbs,
we were able to coimmunoprecipitate the endogenous 
 
 
 
-cat-
enin from lysates of exponentially growing C2C12 mouse
myoblasts (Fig 1 B). Together, these results show that the
interaction of FHL2 with 
 
 
 
-catenin is direct and occurs in
yeast as well as in mammalian cells.
In addition to FHL2, we analyzed the interaction pattern
of FHL1 and FHL3 proteins with 
 
 
 
-catenin and 
 
 
 
-catenin
(plakoglobin). Yeast two-hybrid interaction tests showed
that only FHL2 was capable of binding 
 
 
 
-catenin, but not
the related LIM-only proteins, FHL1 or FHL3. In addition
to 
 
 
 
-catenin, FHL2 also bound the armadillo repeat protein
(
 
 
 
-catenin), but not the vinculin-like 
 
 
 
-catenin (Fig. 2 A).
The specificity of the FHL2–
 
 
 
-catenin interaction was con-
firmed by coprecipitation experiments after myc-tagged
 
 
 
-catenin and GST-tagged FHL proteins were coexpressed
in HEK 293 cells. High levels of 
 
 
 
-catenin were only present
in GST–FHL2 complexes (Fig. 2 B; lane 4, first panel), al-
though a very weak interaction was also noticed with FHL1.
Reciprocally, only the GST-tagged FHL2 protein was found
in immunocomplexes precipitated with myc-specific antibod-
ies (Fig. 2 B; lane 4, third panel). These data clearly confirm
the specificity of FHL2–
 
 
 
-catenin association.
 
Identification of protein domains important 
for the 
 
 
 
-catenin–FHL2 interaction
 
To understand the molecular basis of the FHL2–
 
 
 
-catenin as-
sociation, we wished to identify the interaction domains on
both proteins. For this purpose, we created a series of deletion
mutants for 
 
 
 
-catenin and FHL2 (Figs. 3 and 4). Our dele-
tion mutant analysis revealed the importance of the 
 
 
 
-catenin
NH
 
2
 
 terminus for binding to FHL2. In yeast interaction as-
Figure 1. Interaction between FHL2 and  -catenin in vitro and in 
vivo. (A) Recombinant GST or GST–FHL2 fusion protein was incubated 
with [
35S]methionine-labeled  -catenin. After extensive washing, 
proteins retained by GST or GST–FHL2 were analyzed together with 
10% of the input material by SDS–PAGE and fluorography. (B) C2C12 
cell lysates were immunoprecipitated (IP) with rabbit pAbs against 
FHL2 or EGFP (negative control) as indicated and analyzed by 
SDS-PAGE and immunoblotting (IB) using the anti– -catenin mAb 
14. The arrows show coprecipitated  -catenin. 
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says, the NH
 
2
 
 terminus alone (aa 1–132) still showed binding,
whereas the armadillo repeat region alone or the COOH-ter-
minal half of 
 
 
 
-catenin failed to do so (Fig. 3 A). Consistent
with the yeast two-hybrid data, full-length 
 
 
 
-catenin and a
fragment containing the first armadillo repeat in addition to
the NH
 
2
 
 terminus could be coprecipitated equally well with
FHL2 after coexpression in HEK 293 cells (Fig. 3 B). Because
we could not observe any interaction of FHL2 with the NH
 
2
 
terminus of 
 
 
 
-catenin alone, our data indicate that the NH
 
2
 
-
terminal part of 
 
 
 
-catenin is sufficient for protein association
in yeast; but in mammalian cells, addition of the first arma-
dillo repeat is necessary for strong binding to FHL2.
To identify the part of the FHL2 molecule interacting
with 
 
 
 
-catenin, deletion mutants of FHL2 containing vari-
ous numbers of LIM domains were tested for their interac-
tion with full-length 
 
 
 
-catenin in yeast cells (Fig. 4). Only
the full-length FHL2 showed a strong interaction with
 
 
 
-catenin, and deletion of any LIM domain either abolished
or markedly reduced the binding to 
 
 
 
-catenin. The LIM1-4
mutant lacking the first zinc finger motif was still able to
bind 
 
 
 
-catenin (this shortened form of FHL2 was also used
in the original screen of the myoblast cDNA library),
whereas the LIM2-4 mutant hardly showed any positive
LacZ staining with the few colonies that resulted. The FHL2
deletion mutants showed the same interaction pattern for
 
 
 
-catenin. Together, these data show that most of the FHL2
molecule, except the NH
 
2
 
-terminal half LIM domain, is
necessary for a strong interaction with 
 
 
 
-catenin, whereas
the NH
 
2
 
 terminus plus the first armadillo repeat region of
 
 
 
-catenin molecule is needed for binding to FHL2.
Figure 2. Specificity of interaction of FHL proteins with  -catenin, 
 -catenin, and  -catenin. (A) Yeast Y190 cells were cotransformed 
with GAL4-DNA–binding domain (BD) and GAL4–activation domain 
(AD) chimeric constructs. The interaction was evaluated 
using a  -Gal filter assay as described in Materials and methods. 
The interactions of FHL proteins with AD-FHL2 or the empty 
AD-vector represent positive or negative controls. (B) HEK 293 cells 
were transiently transfected with cDNA constructs as indicated. 
After 34 h, RIPA cell lysates were divided into two parts and proteins 
were either precipitated (P) with glutathione-conjugated Sepharose 
beads for GST-tagged proteins or immunoprecipitated (IP) with the 
antibody 9E10 for myc-tagged proteins. The coprecipitated proteins 
were analyzed in immunoblots (IB) with appropriate antibodies. 
After the first immunodetection, the blots were stripped and 
redeveloped with antibodies against GST- or myc-tag to ascertain 
the amount of precipitated proteins.
Figure 3. The NH2 terminus of  -catenin is sufficient for binding 
to FHL2. (A) Yeast Y190 cells were cotransformed with GAL4-
DNA–binding domain (FHL2) and GAL4–activation domain 
( -catenin) chimeric constructs, and protein–protein interactions 
were evaluated by a  -Gal filter assay. The numbers over the diagrams 
indicate  -catenin amino acids encoded by each construct. The 
arrangement of armadillo repeats is based on Hulsken et al. (1994). 
(B) HEK 293 cells were transiently transfected with cDNA constructs 
as indicated and lysed with RIPA buffer. The presence of myc-tagged 
 -catenin and its deletion mutants in GST–FHL2 precipitates (P) 
were detected by immunoblotting (IB) with myc antibody (top blot). 
To ascertain the amount of precipitated FHL2 protein, the blot was 
redeveloped with antibodies against GST. The blot on the bottom 
shows the expression in transfected cells of full-length myc  -catenin 
and deletion mutants;  -catenin (NT-1) with the NH2 terminus plus 
the first armadillo repeat, and  -catenin (NT) with the NH2 terminus 
only. 10  g of total cell lysates were loaded. 
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FHL2 does not colocalize with 
membrane-bound 
 
 
 
-catenin
 
To further investigate the interaction between 
 
 
 
-catenin
and FHL2, we transfected C2C12 mouse myoblasts with
EGFP-FHL2 and looked for colocalization with endogenous
 
 
 
-catenin by immunofluorescence microscopy. Endogenous
 -catenin showed membrane staining and was concentrated
at cell–cell contact sites (Fig. 5, a and d) where it has been
shown to interact with cadherins (Ozawa and Kemler, 1992;
Redfield et al., 1997). FHL2 was also localized at the cell pe-
riphery, but mostly at focal adhesion sites (Fig. 5, b and e),
as has been described already in various cells (Scholl et al.,
2000; Wixler et al., 2000). Additionally, both proteins
showed a cytoplasmic and nuclear staining. An overlay of
both images clearly indicates that there is no colocalization
of these proteins at the cell periphery (Fig. 5, c and f). The
same results were obtained with immunostaining for endog-
enous FHL2 and  -catenin in cells of epithelial origin. We
could see no colocalization of these proteins at the mem-
brane level, regardless of whether cells had dense cell–cell
contacts or were growing as single cells (unpublished data).
Because there is clearly no colocalization of the two proteins
at the membrane, and taking into account that activated
 -catenin (Behrens et al., 1996; Huber et al., 1996; Yost et
al., 1996), as well as FHL2 (Scholl et al., 2000), are localized
in the nucleus, we hypothesize that their interaction occurs
in the nucleus.
FHL2 represses  -catenin–mediated transcriptional 
activation of TCF/LEF-dependent target genes
Activated  -catenin exerts its function in the nucleus by in-
teracting with members of the TCF/LEF family of transcrip-
tion factors, thereby stimulating transcription of TCF/LEF-
dependent target genes. To test whether expression of FHL2
influences this particular function of  -catenin, we tran-
siently transfected a TCF/ -catenin–dependent TOPflash
reporter construct harboring three TCF/LEF binding sites
upstream of the thymidine kinase minimal promoter into
I28 myoblasts (Irintchev et al., 1997) together with a plas-
mid encoding the phosphorylation-refractory  -catenin sub-
stitution mutant S33A (Fig. 6 A). As expected, the stabilized
 -catenin mutant protein strongly activated transcription of
the reporter gene (115-fold). The FOPflash reporter vector
containing mutated TCF/LEF binding sites was used as a
negative control and was not activated by  -catenin S33A in
the same cells (unpublished data). Significantly, when FHL2
was coexpressed in myoblasts together with  -catenin S33A,
FHL2 strongly repressed the  -catenin–dependent activa-
tion of the reporter gene. Furthermore, the repression effect
was FHL2-specific and clearly dose dependent, as expression
of the myogenic regulatory transcription factor MyoD had
only a slight effect on  -catenin–mediated activation (Fig. 6
A), and transfection of C2C12 cells with increasing amounts
of FHL2 cDNA led to increased repression of  -catenin–
mediated activation of the reporter gene (Fig. 6 B, bars rep-
resent fold repression).
To further describe the FHL2-mediated transcriptional in-
hibition, we studied whether this effect could also be ob-
served with endogenous  -catenin under conditions of stable
high expression of FHL2 protein. For this purpose, we trans-
fected the TOPflash luciferase reporter vector into mock- or
FHL2-infected C2C12 cells. In the mock-infected cells, a
high basal level of TOPflash reporter gene activity was mea-
sured, suggesting a high level of transcriptionally active en-
dogenous  -catenin (Fig. 6 C) because the FOPflash was not
active in the same cells (not depicted). Only a slight induc-
tion of reporter gene activity was seen when the amount of
 -catenin was recombinantly increased, probably due to the
Figure 4. Identification of the minimal binding site on FHL2 for 
 -catenin and  -catenin by yeast two-hybrid assays. Yeast Y190 
cells were cotransformed with GAL4-DNA–binding domain and 
GAL4–activation domain chimeric constructs and protein–protein 
interactions were evaluated by a  -Gal filter assay. The known 
interaction of FHL2 with its own subdomains was used as a positive 
control, and the empty AD-vector served as a negative control.
Figure 5. Subcellular localization of FHL2 and 
 -catenin. C2C12 cells cultured on coverslips 
were transiently transfected with EGFP–FHL2. 
Cells immunostained with anti- –catenin mAb 
and Alexa-conjugated goat anti–mouse polyclonal 
antibody were analyzed by fluorescence micros-
copy. Although  -catenin (red) is concentrated at 
the membrane and at cell–cell contacts, EGFP–
FHL2 (green) is concentrated at focal adhesion 
sites. The merged images show no colocalization 
of the two proteins at membrane level. Panels a–c 
and d– f represent pictures taken with 40  or 63  
objectives, respectively. Bars,  10  m.FHL2 promotes myoblast differentiation | Martin et al. 117
high level of endogenous  -catenin, but recombinant FHL2
introduced by transfection strongly repressed the basal activ-
ity of the luciferase reporter (Fig. 6 C, 47-fold). However, af-
ter coexpression of recombinant  -catenin and FHL2, only a
weak repression was observed (Fig. 6 C, twofold). Compared
to the control cells, the FHL2-expressing cell line showed a
clear reduction of the basal transcription level (Fig. 6 D, 21-
fold compared to the control cells [note the different scales of
y axes]), and only a marginal effect could be achieved by ad-
ditional expression of recombinant  -catenin alone. Impor-
tantly, this effect was abolished when FHL2 was transfected
into these cells in addition to  -catenin (Fig. 6 D).
Together, these data suggest that the observed FHL2-
mediated inhibition of  -catenin–induced transcriptional activ-
ity in myoblasts was specifically dependent on expression of
FHL2. Because FHL2 is known to act as a transcriptional
coactivator in various cellular contexts including HEK 293
embryonal kidney cells, we also analyzed the effects of FHL2
on  -catenin–dependent transcription in this cell line (Fig.
6 E). Expression of  -catenin stimulated reporter gene activ-
ity, and coexpression of FHL2 proteins synergistically en-
hanced the transcriptional activity of  -catenin. Expression
of FHL2 alone had only a marginal effect on reporter gene
transcription. These data indicate a cell type–dependent reg-
ulation of  -catenin function by FHL2, i.e., inhibition in
myoblasts (Fig. 6, A–D) and stimulation in HEK 293 cells
(Fig. 6 E). In an additional assay using Xenopus embryos,
ventral overexpression of FHL2 (but not FHL3) was able to
block  -catenin–induced axis duplication (Fig. 6 F). This ef-
fect was specific with respect to  -catenin, as FHL2 was un-
able to interfere with axis duplication triggered by siamois,
which is a direct downstream target of  -catenin/LEF sig-
naling. Although FHL2 has been described as a transcrip-
tional coactivator (Fimia et al., 2000; Muller et al., 2000),
we believe this is the first study implicating FHL2 in tran-
scriptional repression.
FHL2 contains an autonomous transcriptional 
repression domain
We then investigated whether FHL2 possesses autonomous
repression activity regardless of  -catenin interaction. Be-
cause no DNA binding site for FHL2 is known, the full-
length FHL2 was fused to the GAL4-DNA binding domain
and the GAL-FHL2 chimera was tested in transient transfec-
Figure 6. FHL2 influences  -catenin–mediated activation of 
TCF/LEF-dependent transcription. (A) TOPflash luciferase reporter 
plasmid was cotransfected with  -catenin S33A and the indicated 
amounts of FHL2 or MyoD (as a control) cDNAs into I28 mouse 
myoblast cells. Luciferase activity is given in relative light units 
(RLU). Basal activity of the TOPflash promoter was measured in 
the presence of empty expression vector to maintain equivalent 
amounts of transfected DNA. Results shown are the average of three 
independent transfections. (B) C2C12 cells were cotransfected with 
constant amounts of TOPflash plasmid and  -catenin S33A, and 
with increasing amounts of FHL2 plasmid as indicated. Values indicate 
fold repression of the  -catenin–induced reporter gene activity. The 
induction of reporter gene activity by  -catenin alone was arbitrarily 
taken as unity. (C–E) C2C12 cells stably infected with pBabe vector 
alone (C), or pBabe myc-FHL2 vector (D), or HEK 293 cells (E) were 
transfected with TOPflash luciferase reporter plasmid and the 
indicated expression plasmids. (F) Xenopus embryos were injected 
with different RNAs as indicated at the four-cell stage. Bars represent 
the percentage of embryos with duplicated axis at stage 19–23.
n, No. of embryos examined.
Figure 7. FHL2 exhibits an autonomous repression function 
restricted to fusion-competent myoblasts. Increasing amounts of 
GAL-FHL2 plasmid and 1 g 5xUAS tk-luc reporter plasmid were 
cotransfected as indicated into C2C12 (A), Rhabdomyosarcoma (B), 
or HEK 293 cells (C).118 The Journal of Cell Biology | Volume 159, Number 1, 2002
tion assays using a luciferase reporter under the control of a
multimerized binding site for GAL4 ( 5xUAS tk-luc). Al-
though GAL-VP16 strongly activates the transcription of
the reporter gene (unpublished data), GAL-FHL2 showed
a dose-dependent repression of transcriptional activity in
C2C12 myoblasts (Fig. 7 A). To study whether the observed
FHL2-mediated repression of  -catenin function is re-
stricted only to fusion-competent I28 and C2C12 myogenic
cell lines (Fig. 6, A and B), we next examined the transcrip-
tional capacity of GAL-FHL2 in a fusion-incompetent myo-
genic rhabdomyosarcoma cell line and in HEK 293 human
kidney cells. Indeed, the GAL-FHL2 construct, which re-
pressed transcription in the muscle precursor cell line (Fig. 7
A), activated transcription in rhabdomyosarcoma cells as
well as in HEK 293 cells (Fig. 7, B and C). These data indi-
cate that FHL2 exhibits an autonomous repression function
restricted to fusion-competent myogenic lineages, and addi-
tionally confirm the already described autonomous activa-
tion function in other cell types (Muller et al., 2000).
FHL2 does not compete with LEF-1 
for binding to  -catenin
It is well established that  -catenin mediates induction of
target gene transcription by heterodimerizing with members
of the TCF/LEF superfamily (for review see Akiyama,
2000). Because TCF/LEF proteins interact with the arma-
dillo repeat region of  -catenin, we expected from our dele-
tion mutant analyses (Fig. 3) that the observed FHL2-medi-
ated inhibition of transcription is not based on interference
with LEF/TCF factors. Consistent with this prediction, we
could show the formation of an FHL2– -catenin–LEF-1
ternary protein complex in a GST pull-down assay with bac-
terially expressed GST–FHL2 and in vitro–translated myc–
 -catenin and HA–LEF-1 (Fig. 8, lane 8). Furthermore,
FHL2 bound  -catenin (as expected), but not LEF-1 when
incubated with either of these proteins separately (Fig. 8,
lanes 4 and 6), and none of the in vitro–translated proteins
showed an interaction with GST alone (Fig. 8, lanes 3, 5,
and 7). Moreover, in coimmunoprecipitation experiments
from transfected HEK 293 cells, LEF-1 did not prevent in-
teraction of FHL2 with  -catenin (unpublished data). Thus,
our data demonstrated that FHL2 does not compete with
LEF-1 for binding to  -catenin, and reveals the existence of
a ternary complex of these three components in vitro.
FHL2 overexpression increases differentiation 
of myoblasts into myotubes
To show the functional relevance of the FHL2– -catenin
interaction, we stably expressed myc-tagged recombinant
FHL2 in C2C12 mouse myoblasts. Cells infected with the
myc-vector only and selected for G418 resistance were used
as a control. When cultivated in medium with low levels of
growth factors, control C2C12 cells underwent myogenesis
in vitro and differentiated into well-developed myotubes
within 5 days (Fig. 9 A, top). The FHL2-overexpressing cells
tended to fuse even in growth medium as soon as cell mono-
layers became confluent, but subsequently died when culti-
vation in growth medium was continued. However, if trans-
ferred to differentiation medium, these cells start to fuse and
form myotubes at day 1 after medium change, and fusion
began at lower cell densities than it was usually the case with
control cells (Fig. 9 A, bottom). The efficiency of myotube
formation as well as the longevity of myotubes and the regu-
larity of their shape was also increased. Already, by day 3 af-
ter the start of differentiation, we observed many well-devel-
oped myotubes organized into parallel-running filamentous
bundles. In control cell monolayers, such well-organized
Figure 8.  -Catenin forms a ternary protein complex with FHL2 
and LEF-1. Recombinant GST–FHL2 (lanes 4, 6, and 8) or GST (lanes 
3, 5, and 7) proteins were incubated with [
35S]methionine-labeled 
 -catenin (lanes 3 and 4) or [
35S]methionine-labeled LEF-1 (lanes 5 
and 6), or with both (lanes 7 and 8). After extensive washing, proteins 
retained by GST or GST–FHL2 were analyzed together with 10% of 
the input material (lanes 1 and 2) by SDS–PAGE and fluorography.
Figure 9. Ectopic expression of FHL2 promotes differentiation of 
C2C12 myoblasts. (A) C2C12 myoblasts infected with retroviruses 
containing the pBabe vector alone (control) or pBabe with myc-FHL2 
(FHL2) were cultured in growth medium until 90–95% confluency 
(day 0) and then shifted to differentiation medium (days 1–5). (B) 
Lysates (20  g protein/lane) from cells cultured in growth medium 
(day 0) or in differentiation medium (days 1–5) were immunoblotted 
with anti-myc mAb 9E10, anti-FHL2 mAb, anti– -catenin mAb 14, 
anti-MyHC mAb NOQ7.5.4D, or anti–cyclin D1 mAb DCS-6.FHL2 promotes myoblast differentiation | Martin et al. 119
bundles were never seen even by day 5, rather the myotubes
formed showed a more amorphous and irregular shape than
the FHL2-overexpressing cells.
The expression pattern of the recombinant FHL2 protein
as well as that of endogenous  -catenin did not change dur-
ing the time of cultivation in differentiation medium (Fig. 9
B), which suggests that the observed accelerated myotube
formation was due to stable expression of FHL2. Interest-
ingly, ectopic expression of FHL2 molecules leads to in-
creased expression of the endogenous FHL2 protein, which
however, decreased during differentiation. The increase of
endogenous FHL2 was noticed in all FHL2-overexpressing
C2C12 cell lines we generated (unpublished data).
Differentiation processes are usually associated with inhi-
bition of cell proliferation and transcriptional activation of
particular genes that are characteristic for the differentiated
type of cells or tissue. One of the most prominent markers
for differentiated muscle cells is the muscle-specific myosin
protein. Therefore, we examined whether the ectopic FHL2
protein influences muscle-specific gene expression. Results
presented in Fig. 9 B show that this is indeed the case. Con-
trol cells express low levels of myosin heavy chain (MyHC)
when kept in growth medium, and induction of the muscle-
specific protein is first detectable 48 h after switching the
cells to differentiation medium. In sharp contrast, the FHL2
cells express high levels of MyHC even in growth medium,
and this high level of the protein is maintained or slightly in-
creased during differentiation.
One of the proteins whose expression is regulated by the
 -catenin–TCF complex transcriptional complex is the
cell cycle regulation protein, cyclin D1 (Shtutman et al.,
1999; Tetsu and McCormick, 1999). Western blot analysis
showed that after switching the cells into differentiation me-
dium, cyclin D1 expression was rapidly down-regulated in
both control and FHL2-overexpressing cells (Fig. 9 B). In-
terestingly, the expression of cyclin D1 protein was slightly
decreased even in logarithmically growing FHL2-C2C12
cells compared to that of mock-infected cells. This observa-
tion was in agreement with the slight reduction in prolifera-
tive rate of FHL2-C2C12 cells when compared to control
cells (unpublished data). Thus, the accelerated myogenesis
of FHL2-overexpressing C2C12 myoblasts correlated well
with the enhanced down-regulation of cyclin D1. Although
the down-regulation of cyclin D1 by FHL2 was reproduc-
ible, the extent varied between different cell lines.
Discussion
In this paper, we show that the four and a half LIM-domain
protein FHL2 is a novel  -catenin binding protein. Initially
identified in a yeast two-hybrid screen, the interaction be-
tween FHL2 and  -catenin was confirmed in both direct in
vitro pull-down assays as well as in coimmunoprecipitation
experiments. Using deletion mutants, we showed that the
NH2 terminus together with the first armadillo repeat of
 -catenin is sufficient for its association with FHL2, whereas
the four LIM domains of the FHL2 protein were required
for binding to  -catenin. Furthermore,  -catenin is able to
bind simultaneously to FHL2 and the transcription factor
LEF-1, forming a ternary protein complex. When expressed
in myoblasts either alone or together with  -catenin, FHL2
represses LEF/TCF-induced transcriptional activity and pro-
motes myoblast differentiation, triggering myotube forma-
tion and expression of muscle-specific genes.
The involvement of FHL proteins in muscle cell function
was suggested from observations that FHL1, FHL2, and
FHL3 proteins are highly expressed in skeletal and cardiac
muscles, and are differentially regulated during myogenesis
(Morgan and Madgwick, 1999). Furthermore, FHL2 is
down-regulated in rhabdomyosarcoma cells, localized in
Z-disks of mature muscles, and like FHL3, is found in focal
adhesion complexes of growing myoblasts (Genini et al.,
1997; Scholl et al., 2000; this paper). However, despite their
structural similarity and the fact that all three FHL proteins
are involved in transcriptional regulation (Muller et al.,
2002), only FHL2 showed an interaction with  -catenin in
our experiments. Thus, although being involved in muscle
function or differentiation, the FHL proteins apparently ex-
ercise their particular functions in different ways.
The specificity of the FHL2 and  -catenin interaction was
confirmed in coimmunoprecipitation assays with GST-
tagged FHL proteins as well as after injection of FHL and
 -catenin mRNAs into Xenopus embryos, where only FHL2
significantly inhibited the  -catenin–mediated duplication
of axis formation. Interestingly, FHL2 repressed  -catenin–
dependent transcription only in myoblasts that had not lost
the capacity to differentiate, whereas in tumor cells, includ-
ing muscle-derived rhabdomyosarcoma, we usually observed
the opposite effect, i.e., activation of  -catenin–mediated
transcription. In line with this, transcriptional activation on
expression of FHL2 has been reported in a variety of tumor
cells by other authors (Fimia et al., 2000; Muller et al.,
2002). The fact that FHL2 was also capable of autono-
mously repressing basal promoter activity in myoblasts when
fused to the GAL4-DBD indeed suggests a cell type–specific
effect of FHL2 with regard to transcriptional regulation, and
also indicates the presence of cell type–specific coregulators
for the transcriptional activity of  -catenin.
None of the so far identified interaction partners of
FHL2, such as integrin chains (Wixler et al., 2000), the an-
drogen receptor (Muller et al., 2000), presenilin2 (Tana-
hashi and Tabira, 2000), or CDC47 (Chan et al., 2000),
seem to be directly involved in myoblast differentiation. Our
observation that FHL2 interacts with  -catenin and modu-
lates the  -catenin–mediated transcriptional activity sheds
new light on the role of FHL2 in muscle cells.  -Catenin was
originally identified as a component of the cadherin-based
cell–cell adhesion complex, but is also a transcriptional effec-
tor of the Wg/Wnt pathway. In the presence of Wg/Wnts,
 -catenin is activated and carried to the nucleus where it ac-
tivates target genes by interacting with members of the
TCF/LEF family of transcription factors. We could show
that the interaction of FHL2 with  -catenin represses the
 -catenin–mediated activation of target gene transcription
in proliferating myoblasts, promoting myogenic differentia-
tion. Consistent with our observations,  -catenin has been
implicated in the control of skeletal myogenesis (Goichberg
et al., 2001; Petropoulos and Skerjanc, 2002), but its effect
on myogenic differentiation appears complex. Although
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junctions is important for myogenic differentiation, and
overexpression of  -catenin reduces myogenin expression in
myoblasts (Goichberg et al., 2001), expression of activated
 -catenin in pluripotent P19 embryonic carcinoma cells is
sufficient to induce the transcription of muscle-specific
genes (Petropoulos and Skerjanc, 2002). Our work showed
that FHL2 interferes with transcriptional activation medi-
ated by  -catenin, indicating a delicate balance of  -catenin
activity for proper muscle cell differentiation.
Our interaction studies in yeast identified the NH2 termi-
nus of  -catenin as being sufficient for an interaction with
FHL2, whereas in mammalian cells the first armadillo repeat
in addition to the NH2 terminus was necessary for binding.
In contrast, the full FHL2 molecule, except the first half
LIM domain, was required for strong binding to  -catenin,
suggesting that although LIM domains can fold indepen-
dently, the suprastructure formed by the four LIM domains
of FHL2 is required for binding  -catenin. Interestingly,
FHL2 deletion mutants showed the same interaction pattern
for  -catenin, but its specific binding site for FHL2 has yet
to be determined.
As FHL2 is an adaptor protein without known enzymatic
activity, it might regulate  -catenin function either by
changing its conformation or by competing for binding with
other interacting proteins. It is well established that  -cate-
nin is positively and negatively regulated by numerous pro-
teins. Because transcriptionally active  -catenin hetero-
dimerizes with members of the TCF/LEF family of
transcription factors, negative regulators often compete with
TCF/LEF proteins for binding to  -catenin, thereby pre-
venting the formation of the transcriptionally active TCF/
LEF– -catenin complex (Tago et al., 2000). However, our
results imply that FHL2, when bound to  -catenin, does
not prevent association of the latter with LEF/TCFs. In-
deed, formation of a ternary protein complex was confirmed
in direct binding assays with recombinant FHL2 and in
vitro-translated  -catenin and LEF-1. The same is true for
mammalian cells, where FHL2 does not interfere with the
 -catenin–LEF-1 interaction (unpublished data).
Several   -catenin–interacting proteins that bind to the
NH2 terminus or to the NH2 terminus plus the first armadillo
repeat have been described recently (for review see Zhurinsky
et al., 2000). Among them are  -catenin,  -TrCP, IQGAP,
and the regulators of transcription (NEMO-like kinase, CBP/
p300 histone acetyltransferase, TATA binding protein, and
Pontin52). An intriguing possibility is that FHL2 interferes
with the binding of NEMO-like kinase, pontin52, or CBP/
p300, which negatively or positively regulate the transcrip-
tional activation of target genes by the  -catenin–TCF com-
plex (for review see Zhurinsky et al., 2000). Indeed, depend-
ing on the cell type, our experiments showed either an
inhibition or activation of LEF/TCF-driven transcription. It
is of interest that FHL2 has been characterized as a coactivator
for the transcription factor CREB/CREM, which in turn is
regulated by CBP/p300 (Fimia et al., 2000). It is also an in-
triguing possibility that FHL2 recruits transcriptional repres-
sors or activators to the  -catenin–TCF complex complex.
Our experiments with GAL4-FHL2 fusion protein indicated
that FHL2 functions autonomously as a repressor or activator
of transcription, depending on the cellular context.
An important step in myoblast differentiation is the down-
regulation of cyclin D1 gene expression (Skapek et al., 1995),
which represents one of the transcriptional target genes of
the  -catenin/TCF protein complex. It is interesting that a
clear shift towards enhanced myotube formation and en-
hanced expression of MyHC was noticeable on FHL2 over-
expression, and that this was also accompanied by a down-
regulation of cyclin D1 protein. A lower expression of cyclin
D1 was already noticed in proliferating FHL2-overexpress-
ing cells. Whether these effects are a result of FHL2– -cate-
nin interactions remains to be elucidated. Nevertheless, the
observed down-regulation of cyclin D1 and  -catenin target
gene transcription by FHL2 and the promotion of myogene-
sis might fit with the proposed role of cyclin D1–responsive
cdks as negative regulators of myogenic differentiation via in-
hibition of MyoD function (Wei and Paterson, 2001). Con-
ceivably, FHL2 might modulate the down-regulation of cy-
clin D1 by repressing its transcriptional activator,  -catenin,
and thus indirectly facilitate myogenic differentiation.
Together, our results show a new mode of  -catenin regu-
lation and could explain the putative tumor suppressor po-
tential of FHL2/DRAL (Genini et al., 1997). These findings
now raise additional important questions about the underly-
ing mechanisms. Possible factors that might support the op-
posing effects of FHL2/ -catenin–mediated transcription
activity have to be identified as well as the relationship of
this interaction to the Wnt signaling pathway.
Materials and methods
DNA constructs
For the yeast two-hybrid screen, a cDNA fragment coding for aa 35–279 of
murine FHL2 was inserted into the DNA-binding domain vector pBD-GAL4
Cam (Stratagene). cDNA fragments encoding the complete sequence of
FHL1, FHL2, FHL3, or their deletion mutants were cloned in-frame into
pACT2 or pAS2-1 vectors (CLONTECH Laboratories, Inc.) as described pre-
viously (Wixler et al., 2000). Deletion mutants of  -catenin representing ei-
ther the NH2 terminus only or the NH2 terminus plus one, two, or three ar-
madillo repeats were generated by PCR and cloned in-frame into the pACT2
vector. The pGAD424–GAL4-AD fusion constructs of  -catenin,  -catenin,
and plakoglobin, as well as the other deletion mutants of  -catenin, are de-
scribed elsewhere (Hulsken et al., 1994; Behrens et al., 1996).
For expression in mammalian cells, the cDNA fragment coding for aa
3–279 of murine FHL2 was cloned into the pcDNA3.1/His A vector (Invi-
trogen) or into the pEGFP-C3 vector (CLONTECH Laboratories, Inc.). The
GAL–FHL2 construct was obtained by cloning the FHL2 insert into the
pABgal 94 linker (provided by Aria Baniahmad, University of Marburg,
Marburg, Germany; Baniahmad et al., 1995). The GST-fusion constructs of
FHL1, FHL2, or FHL3 were obtained by cloning into the pEBG vector
(Wixler et al., 2000). The FHL1 cDNA was provided by Po-Hsien Chu
(University of California, San Diego, La Jolla, CA). The wt or myc-tagged
 -catenin S33A mutants (the s33A  -catenin mutant was obtained from
Jörg Stappert, Max-Planck Institute for Immunobiology, Freiburg, Ger-
many; Aberle et al., 1997) were cloned into the pcDNA3.1 plasmid (Invi-
trogen). The myc-tagged  -catenin deletion mutants were generated by
cloning the appropriate inserts from pACT2 vector into the pCS2   MT ex-
pression vector. The MyoD expression plasmid as well as the HA-tagged
LEF-1 constructs were described elsewhere (Lassar et al., 1986; Behrens et
al., 1996). For generation of FHL2 retrovirus stocks, the myc-tagged FHL2
insert was cloned into the pBabe-neo vector. After transfection of GPE  
86 virus-producer cells with pBabe vector alone or pBabe-myc-FHL2, the
cells were selected for G418 resistance, and supernatants from confluent
monolayers were used as retroviral stocks. All constructs were verified by
sequencing before use.
Yeast two-hybrid screen
A mouse cDNA library constructed from I28 skeletal muscle cells after 30-h
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pAD-Gal4 (Stratagene). FHL2 (aa 35–279) in pBD-GAL4 was used as bait
and was sequentially transformed into the PJ69-4A yeast strain along with
the cDNA library. The yeast two-hybrid screen was performed according
to the protocol of Stratagene.
Yeast two-hybrid interaction test
The yeast strain Y190 was cotransformed with the pAS2-1 plasmid con-
taining the GAL4-BD fused with appropriate cDNAs as bait and with
pACT2 or pGAD424 plasmids containing cDNAs fused to GAL4-AD as
prey. Transformants were grown on SD medium lacking the amino acids
leucine, tryptophan, and histidine in the presence of 25 mM 3-amino-
1,2,4-triazole. On day 5, the colonies were tested for LacZ reporter gene
activity in a  -Gal filter assay. The interaction was scored as negative ( )
when no blue colonies were visible after 8 h, and scored as weak ( ), in-
termediate (  ), or strong (   ) when blue colonies became visible af-
ter 8, 4, or 1 h, respectively.
In vitro pull-down binding assays
LEF-1 and  -catenin were synthesized by in vitro transcription–translation in
the presence of [
35S]methionine using the TNT™-coupled reticulocyte lysate
(Promega). The GST–FHL2 fusion protein or GST alone was expressed in
Escherichia coli BL21pLysS. Extracts were incubated with glutathione-coated
Sepharose affinity beads (Amersham Biosciences) for 20 min at RT. After
blocking with 10% milk powder in NENT (100 mM NaCl, 20 mM Tris-HCl,
pH 8.8, 1 mM EDTA, and 0.5% NP40), the GST beads were washed two
times with NENT and equilibrated with TWB (20 mM Hepes, pH 7.9, 60
mM NaCl, 6 mM MgCl2, 8.2% glycerol, 0.1 mM EDTA, and 1 mM DTT).
The beads were then incubated with [
35S]methionine-labeled translation
products in TWB at RT for 1 h, followed by extensive washing with NENT to
eliminate unspecific binding. Proteins adhering to the beads were analyzed
by SDS-PAGE followed by autoradiography or Coomassie staining.
Xenopus injections
RNAs for microinjection into Xenopus embryos were prepared using the
mMESSAGE mMACHINE™ kit (Ambion). Embryos injected with RNA into
both ventral blastomers at the four-cell stage were examined for axis dupli-
cation at stages 19–23. Embryos were injected with RNA in the following
amounts:  -catenin, 50 pg; FHL2, 200–400 pg; FHL3, 200–400 pg; and
siamois, 10 pg.
Cell lines and antibodies
Primary I28 mouse myoblasts were grown in Ham’s F10 nutrient mixture
supplemented with 20% FCS in 5% CO2 atmosphere at 37 C (Kaufmann et
al., 1999). All other cell lines used in this work were grown in DME sup-
plemented with 10% FCS. To generate a cell line stably expressing the re-
combinant myc-FHL2 protein, C2C12 cells were infected with retroviruses
containing either the pBabe-neo vector alone or the pBabe-neo vector
with introduced myc-FHL2. 48 h after infection, the cells were trypsinized
and selected further in medium containing 1,000  g/ml G418. The expres-
sion of myc-FHL2 was analyzed by Western blot procedure using the anti-
myc mAb 9E10.
The mouse mAbs used in this work were purchased from BD Bio-
sciences ( -catenin, clone 14; cyclin D1, clone DCS-6), Oncogene Re-
search Products (myc, clone 9E10), or from Sigma-Aldrich (MyHC, clone
NOG7.5.4D; GST, clone GST-2). FHL2-specific pAb was raised in rabbit
against the full-length protein (aa 3–279). The anti-FHL2 mAb was a gift
from Roland Schule (University of Freiburg, Freiburg, Germany). The HPR-
labeled secondary antibodies for Western blot analysis were purchased
from Jackson ImmunoResearch Laboratories. Alexa Fluor
® 594–labeled
secondary antibodies were purchased from Molecular Probes, Inc.
Reporter gene assays
I28 cells or C2C12 cells (6   10
5/60-mm dish) were transfected with vari-
ous combinations of plasmids using the PolyFect
® Transfection reagent
(QIAGEN). Generally, 0.5  g of reporter gene plasmid DNA (TOPflash,
FOPflash; Upstate Biotechnology) (5xUAS tk-luc; Baniahmad et al., 1995)
was used. The DNA amount of other plasmids varied depending on the ex-
perimental protocol, as indicated in the figure legends, but total plasmid
DNA per dish was kept constant by adding the appropriate amount of
empty expression vector. Each transfection was carried out in triplicate.
Luciferase activities were measured 24 h after transfection using the Lu-
ciferase Assay System (Promega).
Western blotting and immunoprecipitation
Cells were washed twice with PBS and lysed in RIPA buffer supplemented
with 1 mM sodium vanadate, 1 mM PMSF, 5  g/ml leupeptin, and 5  g/ml
aprotinin at RT for 10 min. The lysates were cleared by centrifugation at
10,000 g for 10 min at 4 C. Supernatants were resolved by 10% SDS-
PAGE, and after electroblotting onto nitrocellulose membrane, detection
of proteins was performed with appropriate antibodies using the ECL de-
tection system (Amersham Biosciences). Coimmunoprecipitations were
performed as described previously for M-cadherin and for GST- or myc-
tagged FHL2 proteins (Kaufmann et al., 2000; Wixler et al., 2000). Proteins
were visualized by Western blots using either the NBT/BCIP (Roche) or
ECL detection systems.
Immunofluorescence
Cells grown on coverslips were rinsed in PBS and fixed with 4% PFA in
PBS at RT for 10 min. After fixation, cells were permeabilized by incuba-
tion with 0.2% Triton X-100 in PBS for 10 min, washed with PBS, and in-
cubated with the relevant antibodies diluted in PBS/10% FCS for 1 h.
Primary antibody binding was detected by fluorochrome-conjugated sec-
ondary antibodies. Staining in the absence of primary antibodies con-
firmed the specificity of the immunolabeling. Fluorescence was monitored
with a microscope (Axiophot; Carl Zeiss MicroImaging, Inc.). Pictures
were taken with a digital camera (MagnaFire
®; Optronics) and Image-Pro
®
software (Media Cybernetics, Inc.).
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